PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy

Summary

The objectives of this Phase I/II study are: 1. To find out the maximum tolerated dose (MTD) of PG2 in patients with advanced malignancy receiving chemotherapy and to define a "Study Dose" for Phase II. 2. To evaluate the hematopoietic and immunological responses after administering of PG2. Primarily to study the biological response of PG2, defined as WBC count in this study, and secondarily to study the immunological factors, IL-2, IL-6, TGF-beta, and G-CSF.

Timeline

Start

2001-12

Primary completion

2003-10

Completion

2003-10

Drugs

Indications